LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

ESPERION THERAPEUTICS INC

Deschisă

SectorSănătate

1.01 -0.98

Rezumat

Modificarea prețului

24h

Curent

Minim

1

Maxim

1.05

Indicatori cheie

By Trading Economics

Venit

-19M

-40M

Vânzări

-4.1M

65M

EPS

-0.206

Marjă de profit

-62.243

Angajați

304

EBITDA

-16M

-21M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+530.69% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

48M

206M

Deschiderea anterioară

1.99

Închiderea anterioară

1.01

Sentimentul știrilor

By Acuity

25%

75%

57 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

ESPERION THERAPEUTICS INC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2025, 23:49 UTC

Câștiguri

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 iun. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 iun. 2025, 21:30 UTC

Câștiguri

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Câștiguri

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 iun. 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 iun. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 iun. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 iun. 2025, 23:30 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 iun. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 iun. 2025, 23:19 UTC

Achiziții, Fuziuni, Preluări

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 iun. 2025, 22:06 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:15 UTC

Câștiguri

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 iun. 2025, 21:07 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 iun. 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 20:52 UTC

Câștiguri

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 iun. 2025, 20:51 UTC

Câștiguri

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

ESPERION THERAPEUTICS INC Așteptări

Obiectiv de preț

By TipRanks

530.69% sus

Prognoză pe 12 luni

Medie 6.37 USD  530.69%

Maxim 16 USD

Minim 1.85 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruESPERION THERAPEUTICS INC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

3

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

0.85 / 1.05Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

57 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.